A new extended release formulation (OROS^®) of hydromorphone in the management of pain

References

• BonicaJJEkstromJLSystemic opioids for the management of cancer pain: An updated reviewBenedettiCChapmanCRGironGOpioid Analgesia: Recent Advances in Systemic Administration New YorkRaven PressAdv Pain Res Ther199014425446
   Google Scholar
• World Health OrganizationCancer Pain ReliefGenevaWorld Health Organization1986
   Google Scholar
• JacoxACarrDBPayneRManagement of Cancer Pain Clinical Practice Guideline No 9 Rockville, Md: Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service. AHCPR Publication No. 94-0592. 1994
   Google Scholar
• SchugSAMerryAFAclandRHTreatment principles for the use of opioids in pain of nonmalignant originDrugs1991422282391717222
   PubMed Web of Science ®Google Scholar
• ZenzMStrumpfMTrybaMLong-term oral opioid therapy in patients with chronic nonmalignant painJ Pain Symptom Manage1992769771573287
   PubMed Web of Science ®Google Scholar
• PortenoyRKOpioid therapy for chronic nonmalignant pain: A review of the critical issuesJ Pain Symptom Manage1996112032178869456
   PubMed Web of Science ®Google Scholar
• A Consensus Statement from the American Academy of Pain Medicine and the American Pain Society. The use of opioids for the treatment of chronic painClin J Pain199713689084947
   PubMed Web of Science ®Google Scholar
• RothSHFleischmannRMBurchFXAround-the-clock, controlled-release oxycodone therapy for osteoarthritis-related painArch Intern Med200016085386010737286
   PubMed Web of Science ®Google Scholar
• Guidelines for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis2nd Edition2002American Pain SocietySkokie, IL
   Google Scholar
• Guidelines for the Management of Acute and Chronic Pain in Sickle Cell Disease1999American Pain SocietySkokie, IL
   Google Scholar
• ShiaovaLWallensteinDOutpatient management of sickle cell pain with chronic opioid pharmacotherapyJ Natl Med Assoc200496798498615253332
   PubMed Web of Science ®Google Scholar
• LulliesGUnsere Erfahrungen mit Dilaudid [Our experience with Dilaudid]Munch Med Wochenschr19297014631464
   Google Scholar
• FoleyKMThe treatment of cancer painN Engl J Med198531384952582259
   PubMed Web of Science ®Google Scholar
• HaysHHagenNThirlwellMComparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer painCancer199474180818167521784
   PubMed Web of Science ®Google Scholar
• LesserGJGrossmanSALeongKWIn vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer painPain199s;652–32652728826516
   PubMed Web of Science ®Google Scholar
• MurrayAHagenNAHydromorphoneJ Pain Sympt Manage200529Suppl 5S5766
   PubMed Web of Science ®Google Scholar
• QuigleyCWiffenPA systematic review of hydromorphone in acute and chronic painJ Pain Sympt Manage2003252169178
   PubMed Web of Science ®Google Scholar
• QuigleyCHydromorphone for acute and chronic painCochrane Database Syst Rev20021CD00344711869661
   PubMedGoogle Scholar
• American Pain SocietyPrinciples of Analgesic Use in the Treatment of Acute Pain and Cancer Pain3rd edSkokie, IllAmerican Pain Society1992
   Google Scholar
• DurninCHindIDGhaniSGYatesDBCrossMPharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in young and elderly subjectsProc West Pharmacol Soc200144798011794003
   PubMedGoogle Scholar
• DurninCHindIDGhaniSGYatesDBCrossMDose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR)Proc West Pharmacol Soc200144737411794000
   PubMedGoogle Scholar
• LeeMALengMEFTiernanEJJRetrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatininePalliat Med200115263411212464
   PubMed Web of Science ®Google Scholar
• FainsingerRSchoellerTBoiskinMBrueraECognitive failure and coma after renal failure in a patient receiving captopril and hydromorphoneJ Palliat Care19939153557684078
   PubMedGoogle Scholar
• KaikoRFCommentary: equianalgesic dose ratio of intramuscular/oral morphine, 1:6 versus 1:3FoleyKMInturrisiCEAdv Pain Res TherNew YorkRaven198688794
   Google Scholar
• ChernyNIOpioid analgesics. Comparative features and prescribing guidelinesDrugs1996517137378861543
   PubMed Web of Science ®Google Scholar
• GutsteinHBAkilHOpioid analgesics and antagonistsHardmanJGLimbirdLEGoodman and Gilman’s The Pharmacological Basis of Therapeutics10th edNew YorkMcGraw-Hill2001569619
   Google Scholar
• HoudeRWWallensteinSLBeaverWTEvaluation of analgesics in patients with cancer painLasagnaLInternational Encyclopedia of Pharmacology and Therapeutics Section 6, Clin Pharmacol1OxfordPergamon Press19665997
   Google Scholar
• LawlorPTurnerKHansonJBrueraEDose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective studyPain1997721–279859272790
   PubMed Web of Science ®Google Scholar
• MaxMBLaskaEMSingle-dose analgesic comparisonsMaxMBPortenoyRKLaskaEMThe Design of Analgesic Clinical Trials New YorkRaven PressAdv Pain Res Ther1991185595
   Google Scholar
• Guideline for the Clinical Evaluation of Analgesic DrugsRockville, Md: US Dept of Health and Human Services, Public Health Service, Food and Drug AdministrationFDA Publication1992933093
   Google Scholar
• MahlerDLForrestWHJrRelative analgesic potencies of morphine and hydromorphone in postoperative painAnesthesiology19754260260748347
   PubMed Web of Science ®Google Scholar
• HoudeRWClinical analgesic studies of hydromorphoneFoleyKMInturrisiCEOpioid Analgesics in the Management of Clinical Pain New YorkRaven PressAdv Pain Res Ther19868129135
   Google Scholar
• HoudeRWWallensteinSLBeaverWTClinical measurement of painde StevensGAnalgeticsNew YorkAcademic Press196575122
   Google Scholar
• MoriartyMMcDonaldCJMillerAJA randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer painJ Clin Res1999218
   Google Scholar
• GrossetABRobertsMSWoodsonMEComparative efficacy of oral extended-release hydromorphone and immediate release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trialsJ Pain Symptom Manage200529658459415963867
   PubMed Web of Science ®Google Scholar
• SmithMTNeurotoxicity effects of morphine and hydromorphone evidence implicating the 3-glucuronide metabolitesClin Exp Pharmacol Physiol200027752452810874511
   PubMed Web of Science ®Google Scholar
• WrightAWEMatherLESmithMTHydromorphone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronideLife Sci20016940942011459432
   PubMed Web of Science ®Google Scholar
• ThwaitesDMcCannSBroderickPHydromorphone neuroexcitationPalliat Med200474545550
   Google Scholar
• AngstMSDroverDRLotschJPharmacodynamics of orally administered sustained-release hydromorphone in humansAnesthesiology2001941637311135723
   PubMed Web of Science ®Google Scholar
• HagenNThirlwellMPDhaliwalHSSteady-state pharmacokinetics of hydromorphone and hdyromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphoneJ Clin Pharmacol199535137447538514
   PubMed Web of Science ®Google Scholar
• HaysHHagenNThirlwellMComparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer painCancer1994746180818167521784
   PubMed Web of Science ®Google Scholar
• BrueraESloanPMountBA randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials GroupJ Clin Oncol1996145171317178622092
   PubMed Web of Science ®Google Scholar
• HagenNABabulNComparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer painCancer1997797142814379083166
   PubMed Web of Science ®Google Scholar
• VashiVHarrisSEl-TahtawyAClinical pharmacology and pharmacokinetics of once daily hydromorphone hydrochloride extended-release capsulesJ Clin Pharmacol200545554755415831778
   PubMed Web of Science ®Google Scholar
• WeinsteinSMHeadleyDLShiMGMulticenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone administered every 24 hours to patients with persistent moderate to severe painClin Ther2006281869816490582
   PubMed Web of Science ®Google Scholar
• NadstawekJWartenbergHCSchenkMWirzSHydromorphone in elderly patients with polypathia and with severe painThe Pain Clinic2006185–6403413
   Google Scholar
• FDA ALERT: Alcohol-Palladone™ Interaction; www.fda.gov [07/2005]
   Google Scholar
• Health and Drug AlertsAlcohol-associated rapid release of a long-acting opioidJAMC2005;1737www.cmaj.ca
   Web of Science ®Google Scholar
• ConleyRGuptaSKSathyanG2006Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery formCurr Med Res Opin2005101879189217022845
   PubMed Web of Science ®Google Scholar
• www.ALZA.com – OROS® Oral Delivery Technology; accessed January 2007.
   Google Scholar
• [email protected]; www.janssen-cilag.com – JURNISTA™; accessed January 2007.
   Google Scholar
• DroverDRAngstMSValleMRamaswamyBNaiduSStankiDrVerottaDInput characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteersAnesthesiology200297482783612357147
   PubMed Web of Science ®Google Scholar
• PalangioMNorthfeltDWPortenoyRKBrookoffDDoyleRTJrDornseifBEDamaskMCDose conversion and titration with a novel, once daily, OROS osmotic technology, extended-release formulation in the treatment of chronic malignant or nonmalignant painJ Pain Symptom Manage200223535536812007754
   PubMed Web of Science ®Google Scholar
• SathyanGXuEThipphawongJGuptaSKPharmacokinetic investigation of dose proportionality with a 24 hour controlled-release formulation of hydromorphoneBMC Clin Pharmacol20077317270058
   PubMedGoogle Scholar
• GuptaSSathyanGProviding constant analgesia with OROS hydromorphoneJ Pain Symptom Manage2007332S:S19S24
   Web of Science ®Google Scholar
• SathyanGXuEThipphawongJGuptaSKPharmacokinetic profile of the 24-hour controlled release OROS formulation of hydromorphone in the presence and absence of foodBMC Clinical Pharmacology20077217270055
   PubMedGoogle Scholar
• WallaceMSThipphawongJClinical trial results with OROS hydromorphoneJ Pain Symptom Manage2007332S:S25S32
   Web of Science ®Google Scholar
• WallaceMSkowronskiRKhannaSTudorICThipphawongJEfficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127)Curr Med Res Opin200723598198917519065
   PubMed Web of Science ®Google Scholar
• SathyanGSivakumarKThipphawongJPharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcoholCurr Med Res Opin200824129730518062845
   PubMed Web of Science ®Google Scholar
• WardABozkayaDFleischmannJDuboisDSabatowskiRCaroJJModeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphoneCurr Med Res Opin200723102333234517697453
   PubMed Web of Science ®Google Scholar
• MercandateSOpioid rotation for cancer pain: rationale and clinical aspectsCancer19998691856186610547561
   PubMed Web of Science ®Google Scholar
• GriloRMBertinPScotto di FazanoCOpioid rotation in the treatment of joint pain. A review of 67 casesJoint Bone Spine200269549149412477234
   PubMed Web of Science ®Google Scholar
• WirzSWartenbergHCElsenCWittmannMDiederichsMNadstawekJManaging cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trialClin J Pain200622977077517057558
   PubMed Web of Science ®Google Scholar
• WallaceMRauckRLMoulinDThipphawongJKhannaSTudorICOnce-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration studyInt J Clin Pract200761101671167617877652
   PubMed Web of Science ®Google Scholar
• DunbarPJChapmanCRBuckleyFPGavrinJRClinical analgesic equivalence for morphine and hydromorphone with prolonged PCAPain1996682–32652709121813
   PubMed Web of Science ®Google Scholar
• RappSEEganKJRossBKWildLMTermanGWChingJMA multidimensional comparison of morphine and hydromorphone patient-controlled analgesiaAnesth Analg1996825104310488610865
   PubMed Web of Science ®Google Scholar
• CodaBTanakaAJacobsonRCDonaldsonGChapmanCRHydromorphone analgesia after intravenous bolus administrationPain199771141489200172
   PubMed Web of Science ®Google Scholar
• CollinsJJGeakeJGrierHEHouckCSThalerHTWeinsteinHJTwum-DansoNYBerdeCBPatient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphoneJ Pediatr199612957227288917240
   PubMed Web of Science ®Google Scholar
• MillerMGMcCarthyNO’BoyleCAKearneyMContinuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trialJ Pain Symptom Manage199918191610439568
   PubMed Web of Science ®Google Scholar
• HillJLZacnyJPComparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteersPsychopharmacology (Berl)20001521313911041313
   PubMed Web of Science ®Google Scholar